Handelen Eagle Pharm - EGRX CFD
Toevoegen aan favorieten- Samenvatting
- Historische gegevens
- Evenementen
- Winst- en verliesrekening
- Balans
- Cash Flow
- Eigendom
Handelsvoorwaarden
| Spread | - | ||||||||
|
Overnight-tarief longpositie
Long position overnight fee
Ga naar platform | -0.024068% | ||||||||
|
Overnight-tarief shortpositie
Short position overnight fee
Ga naar platform | 0.001846% | ||||||||
| Tijd van overnight-tarief | 21:00 (UTC) | ||||||||
| Min. verhandelde hoeveelheid | 1 | ||||||||
| Valuta | USD | ||||||||
| Marge | 20% | ||||||||
| Effectenbeurs | United States of America | ||||||||
| Handelscommissie | 0% |
*Information provided by Capital.com
Belangrijkste statistieken
| Prev. Close* | N/A |
| Open* | N/A |
| 1-Jaarlijkse Verandering* | N/A |
| Dagelijks bereik* | N/A |
| 52 wekelijks bereik | 23.87-52.22 |
| Weekgemiddelde volume (10 dagen) | 314.14K |
| Gemiddeld volume (3 maanden) | 3.39M |
| Marktkapitalisatie | 362.04M |
| P/E Ratio | 10.03 |
| Uitstaande Aandelen | 13.08M |
| Omzet | 316.61M |
| EPS | 2.76 |
| Dividend (opbrengst %) | N/A |
| Beta | 0.91 |
| Volgende inkomsten datum | May 8, 2023 |
Alle gegevens zijn afkomstig van Refinitiv, behalve de gegevens gemarkeerd met een sterretje, die zijn afkomstig van Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Slotkoers | Change | Change (%) | Openingskoers | High | Low |
|---|
Eagle Pharm Events
| Tijd (UTC) (UTC) | Land | Evenement |
|---|---|---|
| No events scheduled | ||
- Jaarlijks
- Per kwartaal
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Totale inkomsten | 316.61 | 171.546 | 187.802 | 195.892 | 213.312 |
| Inkomsten | 316.61 | 171.546 | 187.802 | 195.892 | 213.312 |
| Kosten van opbrengsten, totaal | 94.936 | 42.18 | 45.465 | 60.897 | 61.916 |
| Brutowinst | 221.674 | 129.366 | 142.337 | 134.995 | 151.396 |
| Totale bedrijfskosten | 235.65 | 168.777 | 154.848 | 174.077 | 176.696 |
| Verkoop/Algemeen/Admin. Uitgaven, Totaal | 106.626 | 75.322 | 78.598 | 76.37 | 60.509 |
| Onderzoek & Ontwikkeling | 34.088 | 51.275 | 30.785 | 36.81 | 44.419 |
| Ongebruikelijke uitgaven (inkomsten) | 0 | 0 | 10.615 | ||
| Bedrijfsresultaat | 80.96 | 2.769 | 32.954 | 21.815 | 36.616 |
| Renteopbrengsten (-uitgaven), netto Niet-operationeel | -3.774 | -7.275 | -2.015 | -0.517 | -2.578 |
| Overige, Netto | -15.753 | -0.042 | -8.262 | 0.7 | |
| Netto inkomen voor belastingen | 61.433 | -4.548 | 22.677 | 21.998 | 34.038 |
| Netto inkomen na belastingen | 35.642 | -8.627 | 11.989 | 14.313 | 31.903 |
| Netto inkomen voor extra. Posten | 35.642 | -8.627 | 11.989 | 14.313 | 31.903 |
| Netto inkomen | 35.642 | -8.627 | 11.989 | 14.313 | 31.903 |
| Total Adjustments to Net Income | |||||
| Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | 35.642 | -8.627 | 11.989 | 14.313 | 31.903 |
| Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | 35.642 | -8.627 | 11.989 | 14.313 | 31.903 |
| Verwaterd Netto Inkomen | 35.642 | -8.627 | 11.989 | 14.313 | 31.903 |
| Verwaterd Gewogen Gemiddelde Aandelen | 13.0655 | 13.0511 | 13.7714 | 14.1387 | 15.2787 |
| Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | 2.72795 | -0.66102 | 0.87057 | 1.01233 | 2.08808 |
| Verwaterde Genormaliseerde Winst per Aandeel | 3.11654 | -0.66102 | 0.87057 | 1.01233 | 2.73926 |
| Other Operating Expenses, Total | 0 | 0 | -0.763 | ||
| Totale buitengewone posten |
| Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
|---|---|---|---|---|---|
| Totale inkomsten | 60.699 | 65.901 | 74.136 | 115.874 | 42.32 |
| Inkomsten | 60.699 | 65.901 | 74.136 | 115.874 | 42.32 |
| Kosten van opbrengsten, totaal | 19.866 | 23.651 | 23.664 | 27.755 | 12.309 |
| Brutowinst | 40.833 | 42.25 | 50.472 | 88.119 | 30.011 |
| Totale bedrijfskosten | 51.233 | 56.439 | 71.933 | 56.045 | 36.421 |
| Verkoop/Algemeen/Admin. Uitgaven, Totaal | 24.15 | 23.462 | 36.832 | 22.182 | 20.325 |
| Onderzoek & Ontwikkeling | 7.217 | 9.326 | 11.437 | 6.108 | 3.787 |
| Bedrijfsresultaat | 9.466 | 9.462 | 2.203 | 59.829 | 5.899 |
| Renteopbrengsten (-uitgaven), netto Niet-operationeel | -1.663 | -1.591 | -1.008 | -2.712 | -4.53 |
| Overige, Netto | 5.501 | -11.534 | -7.063 | 0.543 | -0.145 |
| Netto inkomen voor belastingen | 13.304 | -3.663 | -5.868 | 57.66 | 1.224 |
| Netto inkomen na belastingen | 8.165 | -7.131 | -9.45 | 44.058 | -6.196 |
| Netto inkomen voor extra. Posten | 8.165 | -7.131 | -9.45 | 44.058 | -6.196 |
| Netto inkomen | 8.165 | -7.131 | -9.45 | 44.058 | -6.196 |
| Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | 8.165 | -7.131 | -9.45 | 44.058 | -6.196 |
| Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | 8.165 | -7.131 | -9.45 | 44.058 | -6.196 |
| Verwaterd Netto Inkomen | 8.165 | -7.131 | -9.45 | 44.058 | -6.196 |
| Verwaterd Gewogen Gemiddelde Aandelen | 13.1694 | 13.1669 | 12.8361 | 12.9068 | 12.8948 |
| Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | 0.62 | -0.54158 | -0.7362 | 3.41355 | -0.4805 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | ||
| Verwaterde Genormaliseerde Winst per Aandeel | 0.6234 | -0.54158 | -0.7362 | 3.41355 | -0.4805 |
- Jaarlijks
- Per kwartaal
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Totaal vlottende activa | 172.606 | 166.065 | 179.449 | 163.844 | 188.697 |
| Geldmiddelen en kortetermijnbeleggingen | 97.659 | 103.155 | 109.775 | 78.791 | 114.657 |
| Geldmiddelen & Equivalenten | 97.659 | 103.155 | 109.775 | 78.791 | 114.657 |
| Totale Vorderingen, Netto | 41.149 | 51.117 | 48.004 | 66.486 | 53.821 |
| Accounts Receivable - Trade, Net | 41.149 | 51.117 | 48.004 | 66.486 | 53.821 |
| Total Inventory | 21.908 | 8.075 | 6.566 | 8.304 | 5.118 |
| Prepaid Expenses | 11.89 | 3.718 | 15.104 | 10.263 | 15.101 |
| Total Assets | 253.732 | 253.19 | 254.554 | 238.603 | 270.06 |
| Property/Plant/Equipment, Total - Net | 1.636 | 2.077 | 5.918 | 2.397 | 6.82 |
| Property/Plant/Equipment, Total - Gross | 7.591 | 7.268 | 10.237 | 5.744 | 9.258 |
| Accumulated Depreciation, Total | -5.955 | -5.191 | -4.319 | -3.347 | -2.438 |
| Goodwill, Net | 39.743 | 39.743 | 39.743 | 39.743 | 39.743 |
| Intangibles, Net | 10.671 | 12.917 | 15.583 | 18.103 | 23.322 |
| Other Long Term Assets, Total | 29.076 | 32.388 | 13.861 | 14.516 | 11.478 |
| Total Current Liabilities | 74.376 | 38.085 | 38.823 | 39.686 | 47.302 |
| Accounts Payable | 16.431 | 6.268 | 5.462 | 9.917 | 27.036 |
| Accrued Expenses | 32.338 | 23.817 | 28.361 | 23.519 | 15.391 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | |||||
| Total Liabilities | 77.279 | 67.179 | 75.38 | 77.841 | 90.916 |
| Total Long Term Debt | 0 | 25.135 | 33.557 | 38.155 | 42.905 |
| Other Liabilities, Total | 2.903 | 3.959 | 3 | 0 | 0.709 |
| Total Equity | 176.453 | 186.011 | 179.174 | 160.762 | 179.144 |
| Common Stock | 0.017 | 0.017 | 0.017 | 0.017 | 0.016 |
| Additional Paid-In Capital | 325.779 | 305.403 | 278.518 | 256.458 | 233.639 |
| Retained Earnings (Accumulated Deficit) | 75.862 | 84.489 | 72.5 | 58.187 | 26.284 |
| Treasury Stock - Common | -225.111 | -203.898 | -171.861 | -153.9 | -80.795 |
| Total Liabilities & Shareholders’ Equity | 253.732 | 253.19 | 254.554 | 238.603 | 270.06 |
| Total Common Shares Outstanding | 12.7914 | 13.057 | 13.6302 | 13.914 | 14.8477 |
| Current Port. of LT Debt/Capital Leases | 25.607 | 8 | 5 | 6.25 | 4.875 |
| Long Term Debt | 0 | 25.135 | 33.557 | 38.155 | 42.905 |
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | |
| Other Equity, Total | -0.094 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Totaal vlottende activa | 240.166 | 172.606 | 171.694 | 175.504 | 163.986 |
| Geldmiddelen en kortetermijnbeleggingen | 69.522 | 97.659 | 99.741 | 108.717 | 105.229 |
| Geldmiddelen & Equivalenten | 69.522 | 97.659 | 99.741 | 108.717 | 105.229 |
| Totale Vorderingen, Netto | 130.858 | 41.149 | 47.081 | 52.659 | 44.868 |
| Accounts Receivable - Trade, Net | 130.858 | 41.149 | 45.335 | 52.659 | 44.868 |
| Total Inventory | 24.818 | 21.908 | 9.315 | 8.294 | 6.862 |
| Prepaid Expenses | 14.968 | 11.89 | 15.557 | 5.834 | 7.027 |
| Total Assets | 320.165 | 253.732 | 256.261 | 264.242 | 259.968 |
| Property/Plant/Equipment, Total - Net | 1.627 | 1.636 | 1.775 | 1.967 | 2.27 |
| Property/Plant/Equipment, Total - Gross | 7.759 | 7.591 | 7.542 | 7.537 | 7.652 |
| Accumulated Depreciation, Total | -6.132 | -5.955 | -5.767 | -5.57 | -5.382 |
| Goodwill, Net | 39.743 | 39.743 | 39.743 | 39.743 | 39.743 |
| Intangibles, Net | 9.94 | 10.671 | 10.799 | 11.505 | 12.211 |
| Other Long Term Assets, Total | 28.689 | 29.076 | 32.25 | 35.523 | 41.758 |
| Total Current Liabilities | 101.642 | 74.376 | 48.431 | 44.664 | 41.973 |
| Accounts Payable | 14.509 | 16.431 | 12.717 | 11.136 | 12.559 |
| Accrued Expenses | 63.408 | 32.338 | 27.714 | 25.528 | 21.414 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 23.725 | 25.607 | 8 | 8 | 8 |
| Total Liabilities | 104.205 | 77.279 | 70.968 | 69.395 | 68.89 |
| Total Long Term Debt | 0 | 0 | 19.489 | 21.371 | 23.253 |
| Long Term Debt | 0 | 19.489 | 21.371 | 23.253 | |
| Other Liabilities, Total | 2.563 | 2.903 | 3.048 | 3.36 | 3.664 |
| Total Equity | 215.96 | 176.453 | 185.293 | 194.847 | 191.078 |
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.017 | 0.017 | 0.017 | 0.017 | 0.017 |
| Additional Paid-In Capital | 328.769 | 325.779 | 320.566 | 316.249 | 312.323 |
| Retained Earnings (Accumulated Deficit) | 119.92 | 75.862 | 82.058 | 87.68 | 84.068 |
| Treasury Stock - Common | -233.164 | -225.111 | -216.466 | -208.195 | -205.33 |
| Total Liabilities & Shareholders’ Equity | 320.165 | 253.732 | 256.261 | 264.242 | 259.968 |
| Total Common Shares Outstanding | 12.6971 | 12.7914 | 12.9446 | 13.0971 | 13.1455 |
| Other Equity, Total | 0.418 | -0.094 | -0.882 | -0.904 |
- Jaarlijks
- Per kwartaal
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Netto-inkomen/Beginsaldo | -8.627 | 11.989 | 14.313 | 31.903 | 51.943 |
| Geldmiddelen uit Operationele Activiteiten | 28.219 | 49.497 | 55.986 | 52.384 | 58.919 |
| Geldmiddelen uit Operationele Activiteiten | 0.764 | 0.872 | 2.131 | 1.155 | 0.932 |
| Amortization | 2.996 | 2.666 | 2.52 | 2.515 | 2.815 |
| Deferred Taxes | -3.618 | -1.511 | 0.152 | -2.468 | 17.289 |
| Niet-Geldelijke Posten | 27.167 | 34.665 | 22.478 | 27.168 | 15.509 |
| Cash Taxes Paid | 10.005 | 6.428 | 6.673 | 2.281 | 10.542 |
| Contant Betaalde Rente | 1.197 | 2.224 | 2.478 | 2.084 | 0.651 |
| Veranderingen in het Operationeel Kapitaal | 9.537 | 0.816 | 14.392 | -7.889 | -29.569 |
| Geldmiddelen uit Investeringsactiviteiten | -5.323 | -18.247 | -0.777 | -0.133 | -5.186 |
| Kapitaaluitgaven | -0.323 | -0.747 | -0.777 | -0.133 | -5.186 |
| Overige Cash Flow investeringsposten, Totaal | -5 | -17.5 | 0 | 0 | |
| Geldmiddelen uit Financieringsactiviteiten | -28.392 | -37.87 | -24.225 | -88.117 | 8.104 |
| Financiering van Cash Flow Posten | -1.577 | -1.525 | -0.524 | -19.877 | -1.192 |
| Uitgifte (Aflossing) van aandelen, netto | -18.815 | -31.345 | -17.701 | -64.49 | -39.454 |
| Nettowijziging in Geldmiddelen | -5.496 | -6.62 | 30.984 | -35.866 | 61.837 |
| Uitgifte (Aflossing) van Schulden, Netto | -8 | -5 | -6 | -3.75 | 48.75 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 44.058 | -8.627 | -2.431 | 3.191 | -0.421 |
| Cash From Operating Activities | -16.611 | 28.219 | 20.138 | 19.071 | 10.478 |
| Cash From Operating Activities | 0.177 | 0.764 | 0.575 | 0.378 | 0.19 |
| Amortization | 0.731 | 2.996 | 2.118 | 1.412 | 0.706 |
| Deferred Taxes | -2.432 | -3.618 | -2.533 | 1.119 | 0.902 |
| Non-Cash Items | 6.616 | 27.167 | 17.689 | 10.989 | 1.378 |
| Cash Taxes Paid | 0.041 | 10.005 | 6.303 | 4.3 | 0.267 |
| Cash Interest Paid | 0.265 | 1.197 | 0.917 | 0.625 | 0.321 |
| Changes in Working Capital | -65.761 | 9.537 | 4.72 | 1.982 | 7.723 |
| Cash From Investing Activities | -0.168 | -5.323 | -5.274 | -5.269 | -5.384 |
| Capital Expenditures | -0.168 | -0.323 | -0.274 | -0.269 | -0.384 |
| Other Investing Cash Flow Items, Total | 0 | -5 | -5 | -5 | -5 |
| Cash From Financing Activities | -11.358 | -28.392 | -18.278 | -8.24 | -3.02 |
| Financing Cash Flow Items | -1.305 | -1.577 | -1.551 | -1.551 | -1.551 |
| Issuance (Retirement) of Stock, Net | -8.053 | -18.815 | -10.727 | -2.689 | 0.531 |
| Issuance (Retirement) of Debt, Net | -2 | -8 | -6 | -4 | -2 |
| Net Change in Cash | -28.137 | -5.496 | -3.414 | 5.562 | 2.074 |
| Naam investeerder | Type investeerder | Percentage uitstaand | Aandelen in bezit | Wijziging aandelen | Datum bezit | Omzetcijfer |
|---|---|---|---|---|---|---|
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 12.5019 | 1635783 | 7863 | 2022-12-31 | LOW |
| Tarriff (Scott L) | Individual Investor | 12.2764 | 1606275 | 70900 | 2023-03-01 | LOW |
| Janus Henderson Investors | Investment Advisor/Hedge Fund | 9.3996 | 1229872 | -9907 | 2022-12-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 7.2761 | 952026 | -59721 | 2022-12-31 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 5.8236 | 761974 | -11708 | 2022-12-31 | LOW |
| Brandes Investment Partners, L.P. | Investment Advisor | 3.1807 | 416177 | -51680 | 2022-12-31 | LOW |
| Adage Capital Management, L.P. | Hedge Fund | 3.0571 | 400000 | 150000 | 2022-12-31 | LOW |
| Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 2.672 | 349606 | -6153 | 2022-12-31 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 2.0379 | 266650 | -7629 | 2022-12-31 | HIGH |
| Acadian Asset Management LLC | Investment Advisor/Hedge Fund | 1.77 | 231587 | -79633 | 2022-12-31 | MED |
| Smith, Graham & Co. Investment Advisors, L.P. | Investment Advisor | 1.7672 | 231222 | -799 | 2022-12-31 | LOW |
| Quoniam Asset Management GmbH | Investment Advisor/Hedge Fund | 1.7569 | 229871 | -55740 | 2022-12-31 | MED |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.5309 | 200305 | 3708 | 2022-12-31 | LOW |
| Charles Schwab Investment Management, Inc. | Investment Advisor | 1.2452 | 162931 | 19807 | 2022-12-31 | LOW |
| Columbia Threadneedle Investments (US) | Investment Advisor/Hedge Fund | 1.2246 | 160236 | -2596 | 2022-12-31 | LOW |
| LSV Asset Management | Investment Advisor | 1.1573 | 151418 | 126068 | 2022-12-31 | LOW |
| Allspring Global Investments, LLC | Investment Advisor/Hedge Fund | 1.1512 | 150628 | 62456 | 2022-12-31 | LOW |
| Scout Investments, Inc. | Investment Advisor | 1.0749 | 140642 | -2342 | 2022-12-31 | MED |
| AQR Capital Management, LLC | Investment Advisor/Hedge Fund | 1.0342 | 135315 | 39400 | 2022-12-31 | LOW |
| Morgan Stanley & Co. LLC | Research Firm | 1.0278 | 134477 | -15478 | 2022-12-31 | MED |
Waarom Capital.com? De cijfers spreken voor zichzelf.
Capital.com Group500K+
Handelaren
92K+
Actieve klanten per maand
$53M+
Maandelijks beleggingsvolume
$30M+
Opgenomen per maand
Handelscalculator
Bereken uw virtuele winst- en verliesrekening indien u een CFD-positie had geopend op een bepaalde datum (kies een datum) en gesloten op een andere datum (kies een datum).
Handelscommissie
0
- 1:1
Hefboom
1:1
- 20
- 100
- 500
- 1000
- 10000
Investering
Positiegrootte (hefboomwerking x investering):
Openingskoers
Slotkoers
Short Long
Eagle Pharm Company profile
Over Eagle Pharm
Eagle Pharmaceuticals, Inc. is een geïntegreerd farmaceutisch bedrijf. Het bedrijf brengt een molecule van preklinisch onderzoek tot wettelijke goedkeuring en op de markt, met inbegrip van ontwikkeling, productie en commercialisering. Het bedrijf identificeert uitdagende te behandelen ziekten van het centrale zenuwstelsel of metabole kritieke zorg therapeutische gebieden, evenals in de oncologie. De Vennootschap biedt drie producten aan: Ryanodex, dantroleennatrium) (Ryanodex), bendamustine ready-to-dilute (RTD) 500ml oplossing (Belrapzo), en snel geïnfundeerde bendamustine RTD (Bendeka). Het bedrijf brengt Ryanodex en Belrapzo op de markt, en Teva Pharmaceutical Industries Ltd. (Teva) brengt Bendeka op de markt. (Teva) brengt Bendeka, een gelyofiliseerde poedervorm van bendamustinehydrochloride, in Japan op de markt.
| Industry: | Proprietary & Advanced Pharmaceuticals |
50 Tice Boulevard, Suite 315
WOODCLIFF LAKE
NEW JERSEY 07677
US
Winst- en verliesrekening
- Annual
- Quarterly
Mensen bekijken ook
Nog steeds op zoek naar een broker die u kunt vertrouwen?
Sluit u aan bij de 500.000+ handelaren die er wereldwijd voor kozen om met Capital.com te handelen